Fluconazole: Difference between revisions
Elcatracho (talk | contribs) |
(Replace manual dosing with dynamic SMW tables (Adult + Pediatric)) |
||
| Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
=== | ===Indications by Disease=== | ||
[[ | {{#ask: [[Has DrugName::Fluconazole]] [[Has Population::Adult]] | ||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
[[ | |?Has Context=Context | ||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Fluconazole]] [[Has Population::Pediatric]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Special Populations== | ==Special Populations== | ||
Revision as of 01:52, 20 March 2026
General
- Type: Antifungal
- Dosage Forms: IV; PO
- Common Trade Names: Diflucan
Adult Dosing
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Acute necrotizing ulcerative gingivitis | 200mg PO daily x 14 days | Immunocompromised |
| Candida vulvovaginitis | 150mg PO once | Preferred; a second dose at 72hrs may be given if still symptomatic |
| Candida vulvovaginitis | 150mg PO q72h x 3 doses | Severe or immunosuppressed |
| Candida vulvovaginitis | 150mg PO qweek x 6 months | Recurrent; long-term suppressive therapy |
| Cryptococcosis | 400mg PO/IV q24hrs x 6-12 months | Pulmonary not AIDS associated |
| Cryptococcosis | 400mg PO q24hrs x 6-12 months | Pulmonary with AIDS |
| Cryptococcosis | 400mg PO q24hrs x 8 weeks | Meningitis consolidation not AIDS |
| Cryptococcosis | 400mg PO q24hrs x 8 weeks | Meningitis consolidation with AIDS |
| Oropharyngeal candidiasis | 200 mg PO on day one, followed by 100 mg daily for two weeks | Adult |
Pediatric Dosing
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Cryptococcosis | 6-12mg/kg PO daily x 8 weeks (max 400mg) | Pediatric Consolidation |
| Oropharyngeal candidiasis | 6 mg/kg PO on day one, followed by 3 mg/kg daily for two weeks | Pediatric |
| Tinea capitis | 6mg/kg PO daily (max 400mg) x 3-6 weeks | Second line |
Special Populations
- Pregnancy Rating: D
- Lactation Risk Categories: safety unknown
- Renal Dosing
- Adult:CrCrl < 50, give usual loading dose x 1 then decrease dose 50%
- Pediatric: CrCrl < 50, give usual loading dose x 1 then decrease dose 50%
- Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- hepatotoxicity
- seizures
- leukopenia
- thrombocytopenia
- anaphylaxis
- steven-johnson syndrome
- QT prolongation
Common
- Nausea
- Rash
- Headache
- vomiting
- diarrhea
- Transaminitis
Pharmacology
- Half-life: 30 hour
- Metabolism: Liver
- Excretion: urine
- Mechanism of Action: inhibits cytochrome P450 and sterol c-14 alpha-demethylation
See Also
==External Links]]
